Clinical Trial Research
Metabolex Initiates Phase 1 Trial of MBX-2982
Published in Lab Law Weekly, April 11th, 2008
The Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBX-2982. Investigators expect to enroll a total of 60 healthy volunteers in the 6-cohort ascending-dose study.
MBX-2982 is an agonist of GPR119, a G-protein coupled receptor (GPCR) that is expressed in pancreatic islets and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2008-04-11)
More Articles from Lab Law Weekly
- AARP
AARP 'Deeply Disappointed' by Supreme Court Decision on Retiree Health Care Benefits - Academy of General Dentistry
AGD Advocacy Conference Connects General Dentists with Congress - Amazon Watch
SEC Complaint Lodged Against Chevron for Hiding $10 Billion Liability in Ecuador - Biopharmaceuticals
R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 - Biotechnology Business
Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration - Burg Simpson Eldredge Hersh & Jardine, P.C.
Peter Burg Appointed as Co-Chair of the Plaintiffs' Steering Committee and the Executive Committee for the Gadolinium-Based Contrast Agents Product Liability Multi-District Litigation - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
